Pci Biotech Holding Asa · LSE:0JGL
Pci Biotech Holding Asa — H1 2023 Earnings Presentation
9 slides from Pci Biotech Holding Asa's earnings presentation, Aug 31, 2023
Slide 1: PCI Biotech - 1H 2023 Interim Report
PCI Biotech - 1H 2023 Interim Report Presentation August 31, 2023 Ronny Skuggedal, CEO / CFO Anders Høgset, CSO Morten Luhr, BD Manager www.pcibiotech.com
Slide 2: Important notice and disclaimer
PCI Biotech Important notice and disclaimer This presentation may contain certain forward-looking Factors that could cause these differences include, but are not limited to, statements and forecasts based on uncertainty, since they implementation of PCI Biotech’s strategy and its ability to further
Slide 3: Table of Contents
Table of Contents Operational review - highlights Key financials Outlook Q&A www.pcibiotech.com 3
Slide 4: Operational review - highlights: gene therapy manufacturing
Operational review - highlights 1H 2023 Maximising yield in gene therapy manufacturing fima NA C Bioprocessing fimaNAc addresses technical needs in manufacturing of gene therapies New data generated to strengthen the first patent application filed in 2H 2022. Continue to advance the application to g
Slide 5: Operational review - highlights: mRNA delivery in skin models
Operational review - highlights 1H 2023 Testing fimaNAc mRNA delivery in human skin models fima NA C 50 fimaNAc strongly enhances mRNA delivery in simplified skin model 40 luciferase activity Dermatology Primary human skin cells growing in 2D culture 30 • Luciferase mRNA protected by delivery vehi
Slide 6: Key financials, Outlook, Q&A
Key financials Outlook Q&A (On
Slide 7: Finance - 1H 2023 key financial figures
Finance 1H 2023 ► Financial run-way estimated towards the end of 2024 Key financial • Cash position of NOK 45 million per end of June figures • NOK -11 million net change in cash for 1H 2023 • Restructuring in 2022 makes comparison with last year figures irrelevant • SkatteFUNN grant application sub
Slide 8: Outlook
Outlook Leveraging the PCI technology platform within bioprocessing, dermatology, and immunotherapy Pipeline 1H 2023 Milestones Milestones 2H 2023 Milestones Laying the ground for • Advance gene therapy manufacturing application towards field testing partnership-driven • Assess collaborative landsca
Slide 9: Enabling intracellular delivery - enquiries
Enabling intracellular PCI Biotech delivery For enquiries: Ronny Skuggedal, CEO / CFO Mobile phone: +47 940 05 757 E-mail: rs@pcibiotech.com www.pcibiotech.com 9